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Abstract
Background: Clinical care teams providing presymptomatic genetic testing often
employ advanced confidentiality practices for documentation and result storage.
However, patient requests for increased confidentiality may be in conflict with the
legal obligations of medical providers to document patient care activities in the electronic health record (EHR). Huntington disease presents a representative case study
for investigating the ways centers currently balance the requirements of EHRs with
the privacy demands of patients seeking presymptomatic genetic testing.
Methods: We surveyed 23 HD centers (53% response rate) regarding their use of the
EHR for presymptomatic HD testing.
Results: Our survey revealed that clinical care teams and laboratories have each
developed their own practices, which are cumbersome and often include EHR avoidance. We found that a majority of HD care teams record appointments in the EHR
(91%), often using vague notes. Approximately half of the care teams (52%) keep
presymptomatic results of out of the EHR.
Conclusion: As genetic knowledge grows, linking more genes to late‐onset conditions, institutions will benefit from having professional recommendations to guide
development of policies for EHR documentation of presymptomatic genetic results.
Policies must be sensitive to the ethical differences and patient demands for presymptomatic genetic testing compared to those undergoing confirmatory genetic testing.
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BACKGROU N D

Clinical laboratories and clinicians follow strict policies for
resulting and storage of data from clinical testing. Usually,
the ordered test is clearly identified and resulted in a way
that the care teams can readily access them. The goal of

clear, accessible records has become even more widespread
with the advent of the electronic health record (EHR). While
genetic information in the EHR has become mainstream,
a few genetic tests still defy these practices for the sake of
confidentiality and to address clinician and patient concerns
about stigmatization and potential discrimination, such as
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in insurability and employment. While there are a handful of these conditions, including frontotemporal dementia
[OMIM: 600274] and autosomal dominant Alzheimer disease [OMIM: 607822, 104300], the most established is the
protocol (HDSA, 2016) for presymptomatic genetic testing
for the presence of the expanded trinucleotide repeat associated with Huntington disease (HD) [OMIM: 143100]. HD
is an autosomal dominant neurodegenerative disorder associated with an expansion of a polymorphic CAG trinucleotide repeat in exon 1 of HTT (Gusella et al., 1983; HDCRG,
1993). While the disease is typically late‐onset, most commonly between the ages of 30–50, individuals of any age can
have HD (Roos, 2010). HD is invariably fatal following a several‐decade progressive decline in motor control, cognitive
faculties and behavioral disturbances. Direct testing in symptomatic patients and presymptomatic testing in at‐risk family
members has been available since 1993. Whereas HD testing
is widely available and fairly routine (Losekoot et al., 2013),
uptake of testing remains low among healthy people at risk
for HD, with fewer than 10% of at‐risk adults in the United
States getting tested. This number is only slightly higher in
countries with a socialized system of health care; in the UK
approximately 17% of people at‐risk for HD are tested (Baig
et al., 2016).
Due to the nearly 100% penetrance of this adult‐onset
condition, the decision for an individual to undergo testing, especially prior to the onset of symptoms, is difficult, as the results may not just affect their life and family
but could also produce serious psychosocial reactions and
lead to future financial planning, educational, and employment complications (Divino et al., 2013). The Genetic
Information Nondiscrimination Act of 2008 (GINA, 2009)
and the Affordable Care Act (ACA, 2010) protect individuals from health insurance discrimination; however, other insurance products such as disability, life, and long‐term care
are not protected by these laws. Thus, a positive presymptomatic HD test result may render an otherwise healthy individual uninsurable. Stakeholders such as the Huntington's
Disease Society of America (HDSA), the American Society
of Human Genetics (ASHG), and the American College of
Medical Genetics and Genomics (ACMG) (ACMG/ASHG,
1998), have stressed extensive pre‐test counseling and confidential testing to “protect the well‐being of individuals who
choose to be tested” (HDSA, 2016). However, maintaining
strict confidentiality of test results is difficult, especially in
the age of the EHR, and may actually compromise patient
care by restricting access to essential diagnostic information.
The field of genetics has wrestled with the possibility of
discrimination since the advent of testing for sickle cell disease (Fulda & Lykens, 2006). Since HD was one of the first
genes for which presymptomatic individuals could choose to
be tested, protocols were established to maintain utmost confidentiality. Results are generally not withheld from the EHR
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except for certain genetic results which are deemed confidential, which is in line with “genetic exceptionalism” (Murray,
1997), namely the practice of treating genetics results differently based on a paternalistic view of patient care. Even
though there was a precedent for constraint in the early days
of HIV testing (Malmberg, Phan, Harmon, & Nauert, 2012;
Williams, 2011), resulting of HIV status in a secure EHR is
generally promoted over paper records, so as to help the individual with their personal care and as a mechanism for public
health reporting (Malmberg et al., 2012).
If strict confidentiality is to be maintained, special precautions must be in place from the moment the patient enters
the clinic, from scheduling, through test ordering, resulting,
to post‐test disclosure and genetic counseling; however, confidentiality of the laboratory test report is a moot point if the
information ends up in a clinician's note. This survey of US
clinical care teams who routinely order HD presymptomatic
testing of individuals addresses the use of the EHR throughout the process as a means to reveal the day‐to‐day issues
with confidentiality in light of EHR use. The ACMG and
ASHG statements regarding HD testing only speak to the
technical standards and guidelines of the test itself (ACMG/
ASHG, 1998) and do not offer recommendations for how the
care team handles the test order or results. The HDSA testing protocol (HDSA, 2016) addresses standards for educating
and supporting individuals being tested; however, it does not
offer standards for managing the legal obligations and challenges of maintaining confidentiality in the EHR. Lastly, the
reporting of a single type of test differently because of confidentiality concerns may need to be examined, and a more
practical protocol may need to be established.

2
2.1

|

M ETHODS

|

Ethical compliance

|

Survey procedures

Neither certification of exemption from UCLA IRB review nor UCLA IRB approval of the proposal and survey
questions were required since the activities did not involve
“human subjects” research as defined by federal regulations
for human subject protections.

2.2

We contacted 43 United States Centers of Excellence listed
on the HDSA website (Huntington's Disease Society of
America, 2019) to query their policies regarding availability of genetic results for presymptomatic individuals. We
emailed the contact person listed on the site, and those who
did not respond were contacted one additional time. Twenty‐
three clinical care teams from 17 states offering HD genetic
testing agreed either to a phone interview or to fill out a written questionnaire regarding their current practices. The single
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member representing the common practice at their institution
included genetic counselors, social workers or clinicians. For
the phone interviews, the survey was sent prior to the conversation, filled out based on their statements, and responses
were confirmed during the phone call. During the phone interviews, representatives were generally more open to sharing their concerns and giving examples of disparities in this
testing population (see Discussion). Two centers rejected the
survey because they do not currently perform presymptomatic genetic testing. Eleven never responded to correspondence, and two responded but did not want to participate. In
five cases, the contact person responded to the email, indicating they were no longer involved with the listed center and
offered to forward the request to the correct person; however,
no response from that center was ever received.
Questionnaires focused on how the HD gene analysis is
ordered, resulted, and stored. The questionnaire was multiple choice, and answers were compiled and counted. Each
member representing their institution was instructed to answer based on how their institution handles presymptomatic
individuals (Figure S1). All answers were kept confidential.
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R E S U LTS

All responding centers perform presymptomatic testing for
expanded HD alleles. A minority of institutions (39%) have
different procedures for individuals choosing to use self‐pay
versus insurance, including sending the test to a different
laboratory and documentation in the EHR (Figure 1). Two
institutions do not allow for a self‐pay option, and one does
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not bill insurance for their services/testing. Approximately
half of the patients (52%) choose to use insurance when possible, and multiple institutions noted that the percentage of
patients choosing insurance to cover the test has been increasing in the past few years. Some institutions noted that
the majority of the individuals choose insurance coverage for
the initial encounter with an ordering physician, even if the
individual chooses self‐pay for the laboratory test. A majority
of institutions (56%) document encounters in the EHR using
the individual's true identity, and 30% of centers allow for the
individual's choice of true identity or a pseudonym. A minority of institutions (9%) have avoided EHR use completely.
However, one of the centers avoiding the EHR is unique as
it is a research center rather than a clinical center, thus allowing it this freedom. Of the institutions documenting the
individuals in the EHR, a majority of clinicians (67%) write
a clear, brief note in the EHR, discussing the testing ordered
and family history, and of the remaining 33%, the clinician
note does not state the testing in question with some referring
to a paper note (“shadow chart”) accessible offline.
A majority of institutions (61%) order testing through
the EHR. Of those, 57% order the test under “HD testing”.
The remaining (43%) teams order tests that are not specific
to HD, such as “Genetic Analysis,” “Special Procedure” or
“Molecular Pathology”. In the latter cases, the care team
wrote in “HD testing”. A minority of institutions (39%) order
by paper requisition or through a laboratory portal not linked
to the individual's EHR. A majority (65%) uses a reference
laboratory for testing, some noting this is unique only to
their self‐pay patients and not their patients using insurance
coverage. The remaining centers (35%) conduct the testing

F I G U R E 1 Results from a clinical care team survey on the process of ordering, resulting, and storage of presymptomatic genetic testing for
Huntington disease. Blue represents tasks completed on the EHR and orange represents tasks completed off the EHR
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in‐house. Interestingly, whether or not the care team ordered
the test through the EHR is not correlated with the type of
laboratory (in‐house or reference) running the test (p = .91).
Of those using a reference laboratory, 47% receive the results via the EHR, and 53% receive results either via fax or
through a laboratory portal. Of those care teams utilizing an
in‐house laboratory, most (75%) received a paper copy, and
25% of the teams noted the results came through the EHR. No
matter the type of laboratory (reference or in‐house), the test
results are accessible to all practitioners in the EHR at 48%
of total institutions, with 54% of these releasing results in
the EHR after the care team has the results appointment with
the individual. A slim majority of institutions (52%) store the
results outside of the EHR, either in a locked cabinet (91%)
or in electronic form (9%). Two institutions upload the results
into the EHR depending on discussions with the patient.
We asked the institutions for their impression as to the
confidentiality concerns of patients seeking presymptomatic
testing. Answers ranged from adamant about patient confidentiality to being content with having results in the EHR
(Figure S1). A minority of institutions (30%) noted the latter; however, three centers do not have an option to avoid the
EHR. Those institutions with the option of anonymity noted
that many to all their patients are concerned enough to have
a discussion. Multiple institutions chose all three options for
this question as, not surprisingly, their patients have different
opinions as to confidentiality of their results.

4
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CO NC LU SION

Strict maintenance of confidentiality in the age of universal
EHR use is difficult. Institutional adherence to the laws of
medical privacy is typically in conflict with the patient's understanding of and wishes for privacy. In the world of EHRs,
particularly nearly universal medical record access when
multiple unrelated institutions use the same EHR platform,
routine clinical care may also infer an ability for providers of
all types to have unfettered access to genetic testing results.
Many patients will view this as a breach of their confidentiality when in reality this access is fully within the bounds of
HIPAA and other privacy policies. Our survey results suggest
that HD centers have a desire to protect the confidentiality
of patients; however, this is becoming increasingly difficult
with the modernization of medical records through EHRs and
legal requirements. Still, centers often create workarounds to
avoid notice in the EHR, which in some cases places an unnecessary burden on the laboratory and clinic at a time when
efficiency in the EHR is preferred, necessary, and sometimes
mandated by the hospital/institution to receive reimbursements from the US government (ARRA, 2009). These workarounds also increase the chances for identification errors,
inability to retrieve results when needed, loss of records, and
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miscommunication. Since testing protocols (HDSA, 2016)
do not address the laws and policies regarding maintenance
of records, each individual center must establish methods
within the bounds of their larger medical institution. While
this survey addresses HD as an example, establishing best
practices for testing and reporting would be helpful for other
cases of presymptomatic genetic testing of individuals harboring detrimental variants or expanded alleles in highly penetrant, late‐onset diseases.

4.1

|

Pre‐test appointments

|

Testing order name

Starting with the act of booking the initial neurologic or genetics appointment, individuals must decide whether or not
to use insurance to pay for the appointment(s). In many cases,
for insurance to cover the appointment(s), a note and (suspected) diagnosis must be documented in the EHR. Centers
that document appointments in the EHR ranged from stating “see paper note” to stating “family history of neurologic
disorder” or “family history of HD”, although most stated
they keep the note as brief as possible. One clinician who
does not mention HD in his note in order to conform to long‐
standing practices at that center felt that not being explicit
as to the testing did not represent appropriate medical care.
A possible solution could be an access‐limiting note, which
would deem such notes as private and appear to maintain
the argument of “genetic exceptionalism” (Green & Botkin,
2003; Murray, 1997). Access‐restricted notes were utilized
at one center; however, recently their institution has blocked
this feature, and all notes are available to the EHR in their
entirety. In order to achieve true informed consent for HD
testing, centers must make an effort to explain to the patient, prior to scheduling their initial testing appointment(s),
the practices and limitations of the documentation and its
visibility in the EHR. This is a difficult task, particularly
as these practices and views of “genetic exceptionalism”
change over time (Evans & Burke, 2008; Murray, 2019;
Rothstein, 2007).

4.2

Clinical laboratory test ordering needs to be clear and concise to avoid mistakes between the care team and laboratory
interface. In many cases in the medical field, the test names
are overly complex and full of abbreviations leading to confusion (Passiment et al., 2013); however, this survey shows
the opposite may have the same effect. One institution uses
the term “Genetic Analysis,” which is a specific “unwritten
code” for HD testing at that laboratory. This unclear orderable may lead to inaccurate orders, which must then be clarified. For example, clinicians not familiar with the “code” may
use this entry to order a multitude of genetic tests, for example, Lynch syndrome. The laboratory then may contact the
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clinician by email to confirm the test, stating they received
an order for “Genetic Analysis” and specifically stating HD
testing in the email, thus breaking the confidentiality that was
originally intended by the discreet name of the test order.
A minority (39%) of care teams avoid the EHR for ordering the test, opting for paper requisition forms or ordering
through a separate laboratory portal. Thus, they are able to
avoid the confidentiality breach that may occur by ordering
the test through the patient's personal EHR. However, some
clinicians and informaticists (Jamoom, Patel, Furukawa, &
King, 2014) argue that ordering through the EHR allows
for efficient use of resources: lower costs, fewer errors, and
quicker turn‐around time.

4.3

|

Storage of results

|

Care team accessibility

When the test is resulted, most institutions do not place results in the EHR, instead handing out a paper copy. While this
maintains confidentiality, avoiding the EHR places a burden
on the individual and the care team to keep results easily accessible. In general, genetic testing reports must be retained
by the laboratory for a minimum of 10 years (Schwartz,
1999). However, individuals may undergo presymptomatic
HD testing many years prior to presenting symptoms of the
disease. In addition, a recent survey found the age of presymptomatic testing has decreased, thus resulting in a longer
period of time between testing and symptoms (Holman et al.,
2018). EHR is more permanent, allowing for easier maintenance of results.
A majority of care teams choose to keep results in a locked
cabinet, which is counter to recommendations that storage
of genetic results be in the EHR (ARRA, 2009; Botkin et
al., 2015; Shoenbill, Fost, Tachinardi, & Mendonca, 2014).
While one can argue that the storage cabinet is safer, it places
excessive burden on the staff member charged with security.
Beyond those concerns, as defined by CLIA and HIPAA, the
patient has a right to access their test reports upon request,
and laboratories subject to CLIA must be able to provide
copies of the requested completed test (CMS et al., 2014;
Schwartz, 1999). Individuals returning decades post‐testing
for a copy of their results will result in an overwhelming
amount of work to retrieve the correct files, which in the interim may have been relocated to remote sites or stored on
media that is no longer readable.

4.4

Accessibility of testing results to the care team is a substantial concern. While the EHR is intended to provide an
accurate medical history, there is the worry of intended and
unintended views of protected health information (PHI).
State laws on the subject of who can receive/access results vary across the US, with a majority allowing for only
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medical professionals who “need to know” having access
to results. In this matter, one could argue that placement
of any type of test where the results were deemed to need
a higher level of protection should not be in a fully accessible EHR.
Maintaining confidentiality of laboratory testing is not
new to the medical records field. Beyond genetics, adolescent care, mental health, and substance abuse treatment
teams have been the most vocal about confidentiality of the
EHR, and thus have built‐in privacy functions in the software platform used. These teams have created “safeguards”
to avoid intended and unintended views of patient PHI,
such as, “soft barriers” or “hard stops”. “Break‐the‐glass”
is intended to warn physicians that they are embarking on
information deemed more private. Those who do “break‐
the‐glass” are then tracked and if the access to that information was deemed inappropriate, may lead to reprimand
or termination based on the breach severity. However, this
feature is generally seen as a pseudo‐protection since it
does not block access for any clinician, nurse, medical student or laboratorian using the interface. Thus, it is only a
perceived protection.
The “hard stops” refer to a block in the information, such
that only those designated by the program can have access
to such data. One principal reason the EHR was developed
was to make data sharing easier with other clinicians; thus,
every informatically placed block leads to a decrease in the
availability of information to another care team who may be
called upon to treat the patient without knowing the historical context (Shenoy & Appel, 2017). Some commented that
it is important for any future care team to know HD results in
case an individual becomes symptomatic and needs proper
care. Thus, keeping genetic test results out of the EHR may
have the potential to cause delays in care, misdiagnoses,
unnecessary repeat testing, or increase costs of care in the
future.
Knowledge of rare, highly penetrant, late‐onset genetic
diseases may be relatively low in general medical practice.
One study found that few providers felt knowledgeable on
the subject of genetics, interpreting genetic test results and
able to care for patients with genetic testing (Hauser, Obeng,
Fei, Ramos, & Horowitz, 2018). For example, a positive presymptomatic test result for HD is not the same as a clinical
diagnosis of HD.
EHR confidentiality extends beyond the health of just the
individual. Some states/insurance carriers will cover in vitro
fertilization (IVF)/preimplantation genetic diagnostic testing
(PGD) (Drazba, Kelley, & Hershberger, 2014); however, to
cover such testing, the genetic variant must be on record. The
same would apply for entry into any clinical trials of HD prevention or therapy. In one case cited in the survey results,
the couple decided that having the positive HD genetic test
recorded in the EHR was a much greater risk than paying
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out‐of‐pocket for IVF with PGD testing, a process known to
cost tens to hundreds of thousands of dollars (Goldman et al.,
2018). Thus, if the EHR included this information in a more
confidential matter, families may be more comfortable with
recording this information in their EHR and not have to make
these difficult decisions.
Many institutions surveyed mentioned the results are
immediately placed in the EHR but withheld completely
or for a period of time from the patient portal. No specific
laws or regulations have been established to address the
degree of information suppressed from a patient‐accessible portal. HIPAA privacy rule deems that patients have
a right to their laboratory results, and these results should
not be withheld based on the sensitive nature or potential
for causing distress to the individual (CMS et al., 2014).
Thus, it may behoove professional bodies to decide if all
genetic results be available in a patient portal to allow patients to access their data which either they or their insurance paid for.

4.5

|

Limited professional guidance

We found a wide range of institutional protocols ranging from full disclosure (clinician note, test ordered and
results) to absence in the EHR. In an era of reliance on
the EHR, the reporting of a single test differently from all
other laboratory results because of confidentiality concerns
may need to be examined and a more practical and uniform
protocol may need to be established by professional bodies. Survey responses revealed a number of other concerns,
such as cumbersome storage and retrieval of test results,
lost results, vague or misleading clinical notes, additional
intralaboratory burdens, and, now that targeted therapies
(Dickey & La Spada, 2018) for HD are emerging, loss of
eligibility for tested patients to enter clinical trials due to
delays in obtaining test results outside of EHRs. The recommended HDSA protocol for testing suggests a level of
confidentiality that was effective when all documentation
was maintained on paper. However, with many hospitals
and laboratories predominantly using EHRs for all appointments, notes, communications with patients, and testing,
we found a large spectrum of practices are occurring in the
field.
Beyond presymptomatic HD testing, institutions also
need to consider which other genetic conditions deserve this
highest level of confidentiality, thus begging the question
of how to make the determination and who should decide.
Testing for asymptomatic carriers of BRCA variants has
been done for roughly the same amount of time; however,
those results are not concealed from the EHR (though some
patients still prefer to pay out of pocket and use a pseudonym). Of course, hereditary breast/ovarian cancer is a
quite different disease with lower penetrance and far more
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options for prevention and treatment. Beyond genetics, HIV
status, which early in the epidemic was kept strictly confidential, is now encouraged to be documented in the EHR
under the argument of effective care for the person (Green
& Botkin, 2003; Herwehe et al., 2012; Safran et al., 1995).
Recommended criteria to guide clinical teams and laboratories when establishing a protocol for confidentiality of
predictive genetic testing do not exist. Therefore, professional recommendations for the appropriate use of EHRs to
document, order, and report genetic testing for late‐onset,
highly penetrant conditions in presymptomatic individuals
are needed to help standardize and optimize current clinical
and laboratory practices.
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